These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
120 related items for PubMed ID: 22640511
1. Extension of the intensive phase reduces relapse but not failure in a regimen with rifampicin throughout. Aung KJ, Declercq E, Ali MA, Naha S, Datta Roy SC, Taleb MA, Hossain MA, Rigouts L, Gumusboga A, Van Deun A. Int J Tuberc Lung Dis; 2012 Apr; 16(4):455-61. PubMed ID: 22640511 [Abstract] [Full Text] [Related]
2. Extension of the intensive phase reduces unfavourable outcomes with the 8-month thioacetazone regimen. Van Deun A, Aung KJ, Hamid Salim MA, Ali MA, Naha MS, Das PK, Hossain MA, Declercq E. Int J Tuberc Lung Dis; 2006 Nov; 10(11):1255-61. PubMed ID: 17131785 [Abstract] [Full Text] [Related]
3. Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? Wilkinson D, Bechan S, Connolly C, Standing E, Short GM. Int J Tuberc Lung Dis; 1998 Jan; 2(1):52-5. PubMed ID: 9562111 [Abstract] [Full Text] [Related]
5. Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB. Hamid Salim A, Aung KJ, Hossain MA, Van Deun A. Int J Tuberc Lung Dis; 2006 Nov; 10(11):1248-54. PubMed ID: 17131784 [Abstract] [Full Text] [Related]
6. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India. Shah AR, Agarwal SK, Shah KV. Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118 [Abstract] [Full Text] [Related]
7. Fluorescein diacetate vital staining allows earlier diagnosis of rifampicin-resistant tuberculosis. Van Deun A, Maug AK, Hossain A, Gumusboga M, de Jong BC. Int J Tuberc Lung Dis; 2012 Sep; 16(9):1174-9. PubMed ID: 22747903 [Abstract] [Full Text] [Related]
8. Relationship between sputum smear grading and smear conversion rate and treatment outcome in the patients of pulmonary tuberculosis undergoing dots--a prospective cohort study. Tiwari S, Kumar A, Kapoor SK. Indian J Tuberc; 2012 Jul; 59(3):135-40. PubMed ID: 23362709 [Abstract] [Full Text] [Related]
9. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda. Bwire R, Borgdorff MW, Sticht-Groh V, Rieder HL, Kawuma HJ, Bretzel G, Rüsch-Gerdes S. East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516 [Abstract] [Full Text] [Related]
10. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment]. Berkani M, Chaulet P, Darbyshire JH, Nunn A, Fox W. Rev Mal Respir; 1986 Jun; 3(2):73-85. PubMed ID: 3726263 [Abstract] [Full Text] [Related]
11. Factors predicting sputum smear conversion and treatment outcomes in new smear-positive pulmonary tuberculosis. Unsematham S, Kateruttanakul P. J Med Assoc Thai; 2013 Jun; 96(6):644-9. PubMed ID: 23951819 [Abstract] [Full Text] [Related]
12. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy. Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione MC. Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571 [Abstract] [Full Text] [Related]
13. Drug susceptibility of Mycobacterium tuberculosis in a rural area of Bangladesh and its relevance to the national treatment regimens. Van Deun A, Aung KJ, Chowdhury S, Saha S, Pankaj A, Ashraf A, Rigouts L, Fissette K, Portaels F. Int J Tuberc Lung Dis; 1999 Feb; 3(2):143-8. PubMed ID: 10091880 [Abstract] [Full Text] [Related]
14. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP. Int J Tuberc Lung Dis; 2012 Oct; 16(10):1335-43. PubMed ID: 23107633 [Abstract] [Full Text] [Related]
15. Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis. Indian J Tuberc; 2007 Apr; 54(2):84-90. PubMed ID: 17575680 [Abstract] [Full Text] [Related]
16. [A-cohort study on the standard short-course chemotherapy program for drug resistant tuberculosis in the rural counties in Eastern China]. Hu Y, Jiang WL, Wang WB, Xu B. Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):540-4. PubMed ID: 19040032 [Abstract] [Full Text] [Related]
17. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Prasad R, Verma SK, Sahai S, Kumar S, Jain A. Indian J Chest Dis Allied Sci; 2006 Jun; 48(3):183-6. PubMed ID: 18610675 [Abstract] [Full Text] [Related]
18. First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. Int J Tuberc Lung Dis; 2012 Jun; 16(6):805-11. PubMed ID: 22390880 [Abstract] [Full Text] [Related]
19. Are we justified in treating for multidrug-resistant tuberculosis based on positive follow-up smear results? Kumar RS, Kumar AM, Claassens M, Banurekha VV, Sekar G, Venkatesan P, Swaminathan S. Int J Tuberc Lung Dis; 2014 Apr; 18(4):449-53. PubMed ID: 24670701 [Abstract] [Full Text] [Related]
20. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. Pérez-Guzmán C, Vargas MH, Martínez-Rossier LA, Torres-Cruz A, Villarreal-Velarde H. Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119 [Abstract] [Full Text] [Related] Page: [Next] [New Search]